Welcome to our dedicated page for Eikon Therapeutics SEC filings (Ticker: EIKN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Eikon Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Eikon Therapeutics's regulatory disclosures and financial reporting.
Lux-affiliated investment funds associated with Eikon Therapeutics director and 10% owner Josh Wolfe reported significant share activity around the company’s IPO. On February 4, 2026, Lux Co-Invest Opportunities II and Lux Total Opportunities each bought 138,888 Eikon common shares in open-market transactions at $18 per share, held indirectly through their general partners.
On February 6, 2026, multiple series of Lux-held preferred stock automatically converted into Eikon common stock immediately prior to the IPO at a 1-for-7.4578 conversion rate. This resulted in indirect common stock positions including 2,387,705 shares held for Lux Ventures V, 1,290,428 shares held for a Lux Co-Invest vehicle, and 2,294,653 shares held for a Lux Total Opportunities fund. Voting and dispositive power is exercised by Lux general partner entities; Wolfe and Peter Hebert may be deemed beneficial owners through those entities, while each disclaims beneficial ownership beyond their pecuniary interest.
Eikon Therapeutics, Inc. reported insider transactions by Lux-affiliated investment entities related to its IPO. On February 4, 2026, Lux Co-Invest Opportunities II, L.P. and Lux Total Opportunities, L.P. each indirectly bought 138,888 shares of common stock at $18 per share in open-market purchases.
On February 6, 2026, several Lux funds indirectly acquired common stock through conversions of preferred stock, including 10,000,000 shares of Series A Preferred Stock and multiple series of A-1, B, B-1, C, C-1 and D Preferred Stock. These preferred shares converted into common stock immediately prior to the closing of Eikon’s initial public offering on a 1-for-7.4578 basis. The Lux entities report indirect beneficial ownership, and the managing members, including director Josh Wolfe and Peter Hebert, disclaim beneficial ownership except to the extent of their pecuniary interests.
Eikon Therapeutics, Inc. reported that, in connection with the closing of its initial public offering on February 6, 2026, it put in place a new legal and governance framework. Immediately prior to the IPO closing, the company’s board and stockholders approved an amended and restated certificate of incorporation and amended and restated bylaws.
The restated certificate of incorporation was filed with the Delaware Secretary of State, and the updated bylaws became effective on February 6, 2026. These documents define the company’s capital structure and core governance rules as a newly public company whose common stock trades on the Nasdaq Stock Market under the symbol EIKN.
Eikon Therapeutics, Inc. is conducting an initial public offering of 21,177,600 shares of common stock at $18.00 per share, for a stated gross offering amount of $381,196,800 and estimated net proceeds to the company, before expenses, of $354,513,024. Underwriters have a 30‑day option to buy up to 3,176,640 additional shares at the same price, less underwriting discounts and commissions. The stock is approved for listing on the Nasdaq Global Select Market under the symbol “EIKN.”
Eikon is a late‑stage clinical biopharmaceutical company focused on oncology, with multiple product candidates in Phase 1/2 and Phase 2/3 trials, including toll‑like receptor and selective PARP1 inhibitors, a WRN helicase inhibitor, and androgen receptor programs. The company estimates cash, cash equivalents and short‑term investments of approximately $336.0 million as of December 31, 2025, but has reported recurring net losses of about $244.6 million for the nine months ended September 30, 2025 and an accumulated deficit of $840.9 million. Its own analysis notes substantial doubt about its ability to continue as a going concern without raising additional capital.